@article{319ebdfd845847d9aaa2fc1ca2592cad,
title = "Reply to “Oral food challenge protocol for food protein-induced enterocolitis syndrome: time for a change?”",
author = "Bird, {J. Andrew} and Maria Crain and Guenther, {Mariam W.} and Parrish, {Christopher P.}",
note = "Funding Information: Conflicts of interest: J. A. Bird reports personal fees for consulting (eg, advisory board participation) from Food Allergy Research and Education, Nutricia North America, Pharm-Olam International Ltd, Pfizer Pharmaceuticals, Prota Therapeutics, Allergy Therapeutics, DBV Technologies, and AllerGenis; speaking honoraria from American College of Allergy, Asthma and Immunology, DBV Technologies, and Abbott Nutrition International; research grants from NIH-NIAID , DBV Technologies , Aimmune Therapeutics , FARE , Astellas , and Genentech outside the submitted work. M. Crain reports being on an allied health advisory board for DBV Technologies and Aimmune Therapeutics for their peanut products. M. W. Guenther has no relevant conflicts of interest. C. P. Parrish reports personal fees from Aimmune Therapeutics, grants and nonfinancial support from DBV Technologies , and grants from NIH-NIAID , Genentech , and Regeneron outside the submitted work. ",
year = "2020",
month = sep,
doi = "10.1016/j.jaip.2020.06.023",
language = "English (US)",
volume = "8",
pages = "2844",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "8",
}